Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
The global gene synthesis market was valued at USD 611 million in 2024. The market is projected to grow from USD 727 million in 2025 to USD 1,865 million by 2031, exhibiting a robust compound annual growth rate (CAGR) of 17.7% during the forecast period.
Gene synthesis refers to the process of chemically synthesizing a strand of DNA base-by-base without the need for a pre-existing DNA template. This contrasts with biological methods like DNA replication or PCR, which require a template strand to initiate the process. Instead, gene synthesis involves the step-wise addition of nucleotides to build a single-stranded molecule, which subsequently serves as a template for creating its complementary strand, resulting in a complete double-stranded DNA fragment. This technology is the fundamental cornerstone upon which the entire field of synthetic biology has been built, enabling the design and creation of novel genetic sequences for research and application.
The market's remarkable growth is significantly driven by rising R&D investments in pharmaceutical and biotechnology sectors, particularly for applications in therapeutic development, vaccine design, and diagnostic tools. The dominance of the Asia-Pacific region, which holds a substantial 38% market share, underscores the global expansion of biotech capabilities, while North America and Europe follow with 33% and 25% shares, respectively. Within the market, the 1001-3000 base pair (bp) segment is the largest, accounting for approximately 35% of the market, as this size range is highly applicable for synthesizing many functional genes. Furthermore, the commercial application segment dominates, holding a commanding 70% share, because gene synthesis is essential for industrial-scale production of enzymes, biofuels, and novel therapeutics.
Accelerating R&D in Synthetic Biology and Therapeutics
The gene synthesis market is experiencing robust growth, primarily fueled by the expanding field of synthetic biology. The drive to design and construct new biological parts, devices, and systems for a wide range of applications, including the development of novel therapeutics, vaccines, and industrial enzymes, creates a foundational demand for custom DNA sequences. The global focus on biologics and cell and gene therapies further intensifies this demand, as these advanced modalities often require the synthesis of complex, optimized genetic constructs that are not readily available from natural sources.
Technological Advancements and Cost Reduction
Significant advancements in oligonucleotide synthesis technologies, coupled with increasing automation and process optimization, have dramatically reduced the cost and increased the speed of gene synthesis. Next-generation sequencing (NGS) also plays a crucial role, providing affordable verification of synthesized genes. This improved accessibility has moved gene synthesis from a specialized, high-cost service to a more routine tool for academic research institutes, pharmaceutical companies, and biotech startups, thereby broadening the market base.
➤ The declining cost of gene synthesis, which has fallen by over 90% in the past two decades, is a primary factor enabling its widespread adoption across diverse sectors.
Beyond life sciences research, gene synthesis is gaining traction in other industries. The agricultural sector utilizes it for crop improvement, while the industrial biotechnology sector employs synthesized genes to engineer microbes for the production of biofuels, bioplastics, and specialty chemicals. The convergence of these diverse applications ensures a multi-pronged driver for continued market expansion.
MARKET CHALLENGES
Stringent Regulatory and Biosecurity Concerns
One of the most significant challenges facing the gene synthesis industry is the complex regulatory landscape, particularly concerning biosecurity. Governments worldwide are implementing stricter screening protocols to prevent the synthesis of pathogens or toxic genes that could be misused. Providers must invest in robust screening software and compliance measures against select agent lists, adding operational complexity and cost. The lack of global harmonization in these regulations further complicates international operations for service providers.
Other Challenges
Technical Limitations with Complex Sequences
While technology has advanced, synthesizing long or highly repetitive DNA sequences remains technically challenging and can suffer from higher error rates. Sequences with extreme GC-content or complex secondary structures can be difficult to produce accurately and efficiently, potentially limiting their application in certain advanced research and development projects.
Intellectual Property and Ethical Issues
The synthesis of genes that are patent-protected raises significant intellectual property concerns, requiring providers to navigate licensing agreements. Furthermore, the ability to create any DNA sequence from scratch continues to provoke ethical debates around "gene editing" and "de novo" creation of biological systems, which can attract public and regulatory scrutiny.
High Initial Capital Investment
The establishment of a gene synthesis facility requires substantial capital investment in specialized equipment, including DNA synthesizers, high-throughput oligo pools, and advanced sequencing instruments for quality control. This high barrier to entry limits the number of new players in the market and can concentrate capabilities among a few large, well-funded companies, potentially restraining competitive pricing and innovation from smaller entrants.
Competition from Alternative Technologies
The gene synthesis market faces competition from alternative gene assembly methods, such as cloning from existing genetic libraries or using CRISPR-based techniques for gene editing within a host organism. For some applications, particularly those involving shorter sequences or modifications to existing genes, these alternatives can be more cost-effective or faster, posing a restraint on the demand for full de novo gene synthesis services.
Expansion in Personalized Medicine and CRISPR-based Therapies
The rapid advancement of personalized medicine, particularly cell and gene therapies, presents a monumental opportunity. These therapies often require the synthesis of patient-specific genetic constructs, such as Chimeric Antigen Receptor (CAR) genes for CAR-T therapies. The growing pipeline of CRISPR-based therapeutics also relies heavily on custom guide RNAs and donor DNA templates, which are products of the gene synthesis market, indicating sustained long-term demand.
Emerging Applications in Data Storage and DNA Digital Data Storage
A nascent but highly promising opportunity lies in the field of DNA digital data storage. Research into encoding digital information into synthetic DNA sequences is advancing, leveraging DNA's incredible storage density and longevity. As this technology develops from proof-of-concept to commercial viability, it could create a massive new market for high-volume, low-cost gene synthesis, fundamentally expanding the industry's scope beyond biological applications.
Growth in Emerging Markets and Outsourcing
There is significant potential for market expansion in emerging economies across Asia-Pacific and Latin America, where government initiatives and growing investments in life sciences research are creating new demand. Additionally, the trend of pharmaceutical and biotech companies outsourcing their R&D activities, including gene synthesis, to specialized contract research organizations provides a steady growth channel for service providers who can ensure quality, speed, and confidentiality.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
1001-3000 bp represents the dominant product type, driven by its critical role in constructing standard gene constructs used extensively in synthetic biology and protein engineering. This mid-length segment offers an optimal balance between synthesis complexity and functional utility for a wide array of research and development applications. There is notable innovation occurring in the Above 5000 bp segment as technological advancements progressively enable more reliable synthesis of longer DNA sequences, which is essential for complex synthetic biology projects. The consistent demand for shorter Below 1000 bp constructs is sustained by applications in areas like gene editing and diagnostic probe development. |
| By Application |
|
Commercial applications are the primary driver of the gene synthesis market, encompassing activities from pharmaceutical and biotechnology companies focused on drug discovery, therapeutic development, and industrial enzyme production. This segment commands significant investment due to the direct path of synthetic genes to commercial products and intellectual property generation. Academic Research remains a vital segment, acting as the foundational source of innovation and methodology development that fuels future commercial applications. The synergy between these segments is strong, with academic discoveries often being rapidly translated into commercial ventures, underscoring the market's dynamic nature. |
| By End User |
|
Pharmaceutical & Biotechnology Companies form the core customer base, leveraging gene synthesis for high-throughput drug target validation, antibody development, and vaccine creation. Their large-scale, recurring demand for custom DNA sequences establishes them as the most influential end-user segment. Academic & Research Institutes are crucial for pioneering new applications and pushing the boundaries of synthetic biology, frequently partnering with commercial entities. Contract Research Organizations are experiencing growing demand as they provide specialized, cost-effective gene synthesis services, allowing clients to outsource this complex process and accelerate their R&D timelines without significant capital investment in internal capabilities. |
| By Service Provider |
|
Full-Service Providers lead this segment by offering comprehensive solutions that include gene design, optimization, synthesis, cloning, and validation, which is highly attractive to clients seeking an end-to-end service. Their scale and reliability make them preferred partners for large projects. Specialty/Boutique Providers cater to niche demands, such as synthesizing difficult sequences or offering ultra-fast turnaround times, appealing to clients with specific, non-standard requirements. While some large biopharma companies maintain In-House Synthesis capabilities for proprietary or highly sensitive projects, the trend favors outsourcing to leverage external expertise and avoid the high costs associated with maintaining cutting-edge synthesis technology. |
| By Technology |
|
Solid-Phase Synthesis remains the industry standard and most widely adopted technology due to its robustness, scalability, and high fidelity for producing accurate DNA sequences. It is the backbone of most commercial gene synthesis services. PCR-Based Assembly methods are valued for their utility in assembling synthetic genes from shorter oligonucleotides, offering flexibility and cost-effectiveness for certain project types. Microchip-Based Synthesis is an emerging and highly innovative segment, enabling massive parallel synthesis that drastically reduces cost per base pair and is poised to revolutionize the market by making large-scale gene synthesis projects more accessible and accelerating the pace of biological design and testing. |
A Market Dominated by Leading Service Providers and Technology Innovators
The global Gene Synthesis market is characterized by a semi-consolidated structure, with the top three competitors GenScript, Thermo Fisher Scientific, and Integrated DNA Technologies (IDT) collectively holding a dominant share of over 53%. These players have established their leadership through extensive service portfolios, significant investment in proprietary synthesis technologies, and global commercial reach. This market concentration is driven by high barriers to entry, including the need for advanced technological infrastructure, substantial capital investment, and stringent quality control standards necessary for producing error-free synthetic genes, especially for sensitive commercial applications which constitute approximately 70% of the market. Competition among these leaders is intense, focusing on synthesis accuracy, turnaround time, cost-effectiveness, and the ability to handle complex and long gene sequences.
Beyond the market leaders, a diverse group of specialized and niche players contribute significantly to the competitive dynamics. Companies such as Twist Bioscience, with its high-throughput silicon-based DNA synthesis platform, and ATUM (formerly DNA2.0), known for its gene design and optimization software, compete on technological innovation. Regional specialists like BBI in China and Eurofins Genomics in Europe have strong footholds in their respective geographic markets. Other players, including Azenta Life Sciences, OriGene, SBS Genetech, and Bio Basic, cater to specific segments such as academic research or offer competitive pricing, thereby fragmenting the remainder of the market. These companies often compete by focusing on specific application areas, customer service, and flexibility in handling custom projects.
List of Key Gene Synthesis Companies ProfiledGenScript
Twist Bioscience
ATUM (DNA 2.0)
OriGene
Eurofins Genomics
BBI
SBS Genetech
Bio Basic
Codex DNA
The global gene synthesis market is demonstrating remarkable growth, projected to surge from a valuation of $611 million in 2024 to $1,865 million by 2031, achieving a compound annual growth rate (CAGR) of 17.7% during the forecast period. This expansion is primarily fueled by the increasing demand from the biotechnology and pharmaceutical industries for custom DNA constructs to accelerate therapeutic development, vaccine research, and diagnostic applications. The market is geographically concentrated, with the Asia-Pacific region leading as the largest market, accounting for approximately 38% of the global share. This dominance is attributed to significant R&D investments, a growing biotech sector, and supportive government initiatives. North America and Europe follow, with shares of 33% and 25%, respectively, maintained by their strong existing research infrastructure and presence of key industry players.
Other TrendsDominance by Product Segment and Application
In terms of product type, the 1001-3000 base pair (bp) length segment is the largest, holding a substantial 35% share of the market. This segment's popularity stems from its critical role in constructing standard genes and pathways, which are fundamental to a wide array of synthetic biology projects. Concerning application, the commercial sector is the predominant driver, accounting for about 70% of market demand. This overwhelming share highlights the technology's central role in industrial applications, including biomanufacturing, enzyme engineering, and the development of novel biologics, far outpacing its use in academic research.
Market Consolidation and Competitive LandscapeThe competitive environment is characterized by a high degree of consolidation, with the top three players Genescript, Thermo Scientific, and IDT collectively holding over 53% of the global market share. This concentration underscores the importance of technological expertise, scalability, and service quality. Companies are actively engaged in strategic initiatives, including mergers, acquisitions, and technological innovations in synthesis accuracy and speed, to strengthen their market positions. The continuous drive for cost reduction and increased throughput in gene synthesis services remains a key trend, enabling broader adoption across various research and commercial fields and shaping the future trajectory of the market.
Regional Analysis: Gene Synthesis MarketEurope
Europe represents a highly significant and mature market for gene synthesis, characterized by a strong academic foundation and a collaborative transnational research environment facilitated by entities like the European Union's Horizon Europe program. The region has a well-established regulatory framework, notably the EU's directives on genetically modified organisms, which provides clarity and structure for commercial activities. Countries such as Germany, the UK, and Switzerland are hubs for biomedical research and biomanufacturing, driving demand for custom gene constructs for both basic research and industrial applications. The market is supported by a growing emphasis on sustainable biotechnology and green manufacturing processes, which increasingly rely on synthetic biology tools. While the market is fragmented across numerous countries, pan-European initiatives help create a cohesive and competitive landscape that fosters innovation and market growth, making it a key challenger to North American dominance.
Asia-Pacific
The Asia-Pacific region is the fastest-growing market for gene synthesis, fueled by rapidly expanding biotechnology sectors, increasing government investments in life sciences, and a growing base of contract research and manufacturing organizations. Countries like China, Japan, and South Korea are making significant strides, with China in particular emerging as a major force due to substantial state-backed initiatives and a large domestic market. The region benefits from cost-competitive manufacturing capabilities and a strong focus on applications in agriculture, industrial enzymes, and biosimilars. While the intellectual property landscape is still evolving, the sheer scale of research activity and manufacturing output creates immense demand for gene synthesis services. The combination of economic growth, strategic government support, and a burgeoning skilled workforce positions the Asia-Pacific region as a critical and dynamic player in the global gene synthesis market with immense future potential.
South America
The gene synthesis market in South America is nascent but showing promising growth, primarily driven by agricultural biotechnology and increasing biomedical research in countries like Brazil and Argentina. The region's strong agricultural sector creates demand for synthetic genes used in developing genetically modified crops resistant to pests and drought. Research institutions are increasingly engaging in genomics and synthetic biology, though funding and infrastructure constraints limit the pace of expansion compared to more developed regions. Collaboration with international partners is common, helping to build local capacity. While the market is relatively small, it represents a significant growth opportunity as local expertise develops and investment in bio-economies increases, focusing on regional needs and resource-based applications.
Middle East & Africa
The gene synthesis market in the Middle East and Africa is in its early stages of development, with growth concentrated in a few key countries that are investing in building their biotechnology capabilities. In the Middle East, nations like Israel and the United Arab Emirates are leading, focusing on medical research and vaccine development, which drives niche demand for synthetic genes. In Africa, South Africa is the most advanced market, with applications largely in agricultural research and combating infectious diseases. The region faces challenges related to funding, infrastructure, and technical expertise, but international collaborations and initiatives aimed at building scientific capacity are helping to foster gradual market development. The long-term potential is significant, particularly in addressing regional health and agricultural challenges through synthetic biology solutions.
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2031. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type (Below 1000 bp, 1001-3000 bp, etc.)
By application (Commercial, Academic Research)
By end-user industry
By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical research institutions
Healthcare providers and diagnostic labs
Contract research organizations
Investors, consultants, and policy makers
-> The global gene synthesis market was valued at USD 611 million in 2024 and is projected to reach USD 1,865 million by 2031.
-> The market is expected to grow at a compound annual growth rate (CAGR) of 17.7% during 2025-2031.
-> Key players include Genescript, Thermo Scientific, Twist Bioscience, IDT, and DNA 2.0 (ATUM), among others.
-> Asia-Pacific holds the largest market share at 38%, followed by North America (33%) and Europe (25%).
-> 1001-3000 base pairs segment dominates with 35% market share.
Our Clients
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates